{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:59:33Z","timestamp":1790791173639,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.esmoop.2025.106033","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:13:20Z","timestamp":1768551200000},"page":"106033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers"],"prefix":"10.1016","volume":"11","author":[{"given":"S.","family":"Alfieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9172-7003","authenticated-orcid":false,"given":"S.","family":"Rota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1644-1981","authenticated-orcid":false,"given":"R.","family":"Roman\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Busico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Conca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tamborini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1294-6859","authenticated-orcid":false,"given":"S.","family":"Cavalieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Buriolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sciortino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9365-2160","authenticated-orcid":false,"given":"A.G.","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Nuzzolese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bergamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Quattrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vingiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3315-2580","authenticated-orcid":false,"given":"L.D.","family":"Locati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Licitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pruneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0582-6170","authenticated-orcid":false,"given":"L.","family":"Agnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.esmoop.2025.106033_bib1","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.21.00449","article-title":"Management of salivary gland malignancy: ASCO guideline","volume":"39","author":"Geiger","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106033_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejso.2017.08.018","article-title":"Epidemiology of rare cancers and inequalities in oncologic outcomes","volume":"45","author":"Gatta","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106033_bib3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bjoms.2014.10.008","article-title":"Tumours of the salivary glands in northeastern China: a retrospective study of 2508 patients","volume":"53","author":"Wang","year":"2015","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"6","key":"10.1016\/j.esmoop.2025.106033_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100602","article-title":"Salivary gland cancer: ESMO\u2013European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"7","author":"van Herpen","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2025.106033_bib6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.oraloncology.2016.12.016","article-title":"Systemic therapy in metastatic salivary gland carcinomas: a pathology-driven paradigm?","volume":"66","author":"Alfieri","year":"2017","journal-title":"Oral Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.106033_bib7","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106033_bib8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/13543784.2019.1598376","article-title":"Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?","volume":"28","author":"Cavalieri","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"10.1016\/j.esmoop.2025.106033_bib9","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/annonc\/mdx399","article-title":"Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies","volume":"28","author":"Ross","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106033_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/cancers9020017","article-title":"Androgen receptor signaling in salivary gland cancer","volume":"9","author":"Dalin","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.esmoop.2025.106033_bib11","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/annonc\/mdg331","article-title":"A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland","volume":"14","author":"Locati","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.106033_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1096068","article-title":"HER2 status in recurrent\/metastatic androgen receptor overexpressing salivary gland carcinoma patients","volume":"12","author":"Cavalieri","year":"2023","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.106033_bib13","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00067","article-title":"Molecular tumor board as a clinical tool for converting molecular data into real-world patient care","volume":"7","author":"Vingiani","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106033_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-64149-7","article-title":"Molecular profiling of pediatric and young adult colorectal cancer reveals a distinct genomic landscapes and potential therapeutic avenues","volume":"14","author":"Busico","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106033_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"issue":"9","key":"10.1016\/j.esmoop.2025.106033_bib16","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106033_bib17","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/hed.23940","article-title":"Clinical activity of androgen deprivation therapy in patients with metastatic\/relapsed androgen receptor-positive salivary gland cancers","volume":"38","author":"Locati","year":"2016","journal-title":"Head Neck"},{"issue":"20","key":"10.1016\/j.esmoop.2025.106033_bib18","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2025.106033_bib19","doi-asserted-by":"crossref","first-page":"6643","DOI":"10.1158\/1078-0432.CCR-06-1759","article-title":"Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma","volume":"12","author":"Perrone","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2025.106033_bib20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2016.09.022","article-title":"A phase II study of sorafenib in recurrent and\/or metastatic salivary gland carcinomas: translational analyses and clinical impact","volume":"69","author":"Locati","year":"2016","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2025.106033_bib21","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/jop.12301","article-title":"Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma","volume":"44","author":"Cortelazzi","year":"2015","journal-title":"J Oral Pathol Med"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106033_bib22","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/his.13281","article-title":"MYB, MYBL1, MYBL2 and NFIB gene alterations and MYC overexpression in salivary gland adenoid cystic carcinoma","volume":"71","author":"Fujii","year":"2017","journal-title":"Histopathology"},{"issue":"19","key":"10.1016\/j.esmoop.2025.106033_bib23","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1158\/1078-0432.CCR-10-0463","article-title":"Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance","volume":"16","author":"Mitani","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106033_bib24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1158\/1078-0432.CCR-15-2867-T","article-title":"Novel MYBL1 gene rearrangements with recurrent MYBL1-NFIB fusions in salivary adenoid cystic carcinomas lacking t(6;9) translocations","volume":"22","author":"Mitani","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.esmoop.2025.106033_bib25","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ng.2643","article-title":"The mutational landscape of adenoid cystic carcinoma","volume":"45","author":"Ho","year":"2013","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106033_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70663","article-title":"Clinical outcomes with notch inhibitors in notch-activated recurrent\/metastatic adenoid cystic carcinoma","volume":"14","author":"Hoff","year":"2025","journal-title":"Cancer Med"},{"issue":"20","key":"10.1016\/j.esmoop.2025.106033_bib27","doi-asserted-by":"crossref","first-page":"32918","DOI":"10.18632\/oncotarget.16464","article-title":"A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma","volume":"8","author":"Goncalves","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.esmoop.2025.106033_bib28","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/1078-0432.CCR-19-2214","article-title":"A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer","volume":"26","author":"Rodriguez","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2025.106033_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2023.106612","article-title":"HER2-targeted therapies for salivary gland cancers","volume":"148","author":"Filippini","year":"2024","journal-title":"Oral Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106033_bib30","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.annonc.2019.11.018","article-title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study","volume":"31","author":"Kurzrock","year":"2019","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2025.106033_bib31","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1200\/JCO.2021.39.15_suppl.6079","article-title":"Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: subgroup analysis of two phase 1 studies","volume":"39","author":"Bando","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2025.106033_bib32","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1200\/JCO.2019.37.15_suppl.6001","article-title":"Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): results from a phase II basket trial","volume":"37","author":"Li","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106033_bib33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40364-024-00565-1","article-title":"HER2-targeted therapies in cancer: a systematic review","volume":"12","author":"Zhu","year":"2024","journal-title":"Biomark Res"},{"key":"10.1016\/j.esmoop.2025.106033_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2025.107280","article-title":"The impact of HER2-Low expression in salivary duct carcinoma: clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapy","volume":"165","author":"Kano","year":"2025","journal-title":"Oral Oncol"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2025.106033_bib35","volume":"42","author":"Curigliano","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.106033_bib36","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1200\/JCO.2025.43.16_suppl.6006","article-title":"SHR-A1811 in HER2-expressing salivary gland cancers: preliminary efficacy and safety results","volume":"43","author":"Chen","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.106033_bib37","doi-asserted-by":"crossref","first-page":"S613","DOI":"10.1016\/j.annonc.2024.08.909","article-title":"849O phase II study of trastuzumab deruxtecan in patients with HER2-positive recurrent\/metastatic salivary gland cancer: results from the MYTHOS trial","volume":"35","author":"Kinoshita","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.106033_bib38","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14737140.2023.2208350","article-title":"Targeting human EGFR 2 (HER2) in salivary gland carcinoma","volume":"23","author":"Wotman","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"10.1016\/j.esmoop.2025.106033_bib39","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.106033_bib40","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s43018-020-0047-1","article-title":"Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors","volume":"1","author":"Razavi","year":"2020","journal-title":"Nat Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2025.106033_bib41","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.106033_bib42","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221119538","article-title":"Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma","volume":"14","author":"Kawakita","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106033_bib43","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0b013e3181d9efcc","article-title":"Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity","volume":"34","author":"Sk\u00e1lov\u00e1","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.esmoop.2025.106033_bib44","author":"Bishop"},{"issue":"15","key":"10.1016\/j.esmoop.2025.106033_bib46","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1200\/JCO.22.02221","article-title":"Phase II clinical trial of axitinib and avelumab in patients with recurrent\/metastatic adenoid cystic carcinoma","volume":"41","author":"Ferrarotto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.106033_bib47","doi-asserted-by":"crossref","DOI":"10.1177\/01455613251324353","article-title":"The role of immunotherapy in salivary gland cancer: a systematic review","author":"Kim","year":"2025","journal-title":"Ear Nose Throat J"},{"key":"10.1016\/j.esmoop.2025.106033_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114127","article-title":"Harmonization of homologous recombination deficiency testing in ovarian cancer: results from the MITO16A\/MaNGO-OV2 trial","volume":"206","author":"Roma","year":"2024","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106033_bib49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.neo.2021.03.008","article-title":"SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets","volume":"23","author":"Freiberger","year":"2021","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106033_bib50","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/PAP.0000000000000298","article-title":"High-grade transformation\/dedifferentiation in salivary gland carcinomas: occurrence across subtypes and clinical significance","volume":"28","author":"Skalova","year":"2021","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.esmoop.2025.106033_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.784","article-title":"660MO Molecular targets in salivary gland cancers: a comprehensive genomic analysis of 1,666 cases","volume":"33","author":"Sivapiragasam","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.106033_bib52","doi-asserted-by":"crossref","first-page":"S1227","DOI":"10.1016\/j.annonc.2024.08.2275","article-title":"LBA36 \u2013 A randomized phase II study to evaluate the efficacy and safety of androgen deprivation therapy (ADT) versus chemotherapy (CT) in patients with recurrent and\/or metastatic, androgen receptor (AR) expressing, salivary gland cancer","volume":"35","author":"Licitra","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.106033_bib53","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2023.1379","article-title":"Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas","volume":"9","author":"Haddad","year":"2023","journal-title":"JAMA Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925019039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925019039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T04:19:25Z","timestamp":1773980365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925019039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2059702925019039"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.106033","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.106033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106033"}}